Media stories about Platinex (NASDAQ:PTX) have been trending somewhat positive on Sunday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Platinex earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.7418929353005 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Shares of Platinex (NASDAQ:PTX) traded down C$0.05 during trading hours on Friday, reaching C$2.99. 303,817 shares of the company’s stock traded hands, compared to its average volume of 87,131. Platinex has a twelve month low of C$1.83 and a twelve month high of C$7.15.

TRADEMARK VIOLATION NOTICE: “Platinex (PTX) Receiving Somewhat Positive Media Coverage, Analysis Finds” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at

Platinex Company Profile

Pernix Therapeutics Holdings, Inc is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.

Insider Buying and Selling by Quarter for Platinex (NASDAQ:PTX)

Receive News & Ratings for Platinex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Platinex Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.